Medicine · 2025
Efficacy and safety of mirikizumab in the treatment of inflammatory bowel disease: A meta-analysis.
СтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xuemei, Si Guifei, Li Yuquan, Yuan Xuemin
Аннотация
BACKGROUND: This meta-analysis explores the efficacy and safety of mirikizumab in treating IBD.
METHODS: A comprehensive search was conducted encompassing randomized controlled trials examining the efficacy of mirikizumab in treating IBD across PubMed, Embase, Cochrane Library, and Web of Science, with a search deadline of November 1, 2023. Quality assessment leaned on the Cochrane manual risk-of-bias evaluation, while Stata 15 undertook the data analysis.
RESULTS: Three randomized controlled studies involving 1602 individuals were finally included. Our meta-analysis suggested that mirikizumab can improve clinical remission (RR = 2.11, 95% CI [1.74, 2.55]), clinical response (RR = 1.68, 95% CI [1.50, 1.89]), endoscopic remission (RR = 1.95, 95% CI [1.65, 2.31]), histologic-endoscopic mucosal improvement (RR = 1.92, 95% CI [1.60, 2.32]) in inflammatory bowel disease (IBD).
CONCLUSION: According to our meta-analysis, mirikizumab is a promising drug in the treatment of IBD.
METHODS: A comprehensive search was conducted encompassing randomized controlled trials examining the efficacy of mirikizumab in treating IBD across PubMed, Embase, Cochrane Library, and Web of Science, with a search deadline of November 1, 2023. Quality assessment leaned on the Cochrane manual risk-of-bias evaluation, while Stata 15 undertook the data analysis.
RESULTS: Three randomized controlled studies involving 1602 individuals were finally included. Our meta-analysis suggested that mirikizumab can improve clinical remission (RR = 2.11, 95% CI [1.74, 2.55]), clinical response (RR = 1.68, 95% CI [1.50, 1.89]), endoscopic remission (RR = 1.95, 95% CI [1.65, 2.31]), histologic-endoscopic mucosal improvement (RR = 1.92, 95% CI [1.60, 2.32]) in inflammatory bowel disease (IBD).
CONCLUSION: According to our meta-analysis, mirikizumab is a promising drug in the treatment of IBD.